Atezolizumab in combination with neoadjuvant chemotherapy and interval cytoreductive surgery for patients with newly diagnosed advanced-stage epithelial ovarian cancer: the AdORN study

Stéphanie Gaillard, Jack Parker, Gloria Broadwater, Linda Duska, Hope Knochenhauer, Kari Ring, Leah McNally, Paula S. Lee, Brittany Davidson, Rebecca Previs, Haley Moss, Layne W. Rogers, Yanwan Dai, Andrew Berchuck, Andrew B. Nixon, John S. Yi, Michael Bookman, Kouros Owzar, Jadee L. Neff, Jose Conejo-Garcia, Angeles Alvarez Secord

Open source

DOI: 10.1016/j.ygyno.2026.06.003
Published: 2026-07
Container: Gynecologic Oncology
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.ygyno.2026.06.003,
  title = {Atezolizumab in combination with neoadjuvant chemotherapy and interval cytoreductive surgery for patients with newly diagnosed advanced-stage epithelial ovarian cancer: the AdORN study},
  author = {Stéphanie Gaillard and Jack Parker and Gloria Broadwater and Linda Duska and Hope Knochenhauer and Kari Ring and Leah McNally and Paula S. Lee and Brittany Davidson and Rebecca Previs and Haley Moss and Layne W. Rogers and Yanwan Dai and Andrew Berchuck and Andrew B. Nixon and John S. Yi and Michael Bookman and Kouros Owzar and Jadee L. Neff and Jose Conejo-Garcia and Angeles Alvarez Secord},
  year = {2026},
  journal = {Gynecologic Oncology},
  doi = {10.1016/j.ygyno.2026.06.003},
  url = {https://doi.org/10.1016/j.ygyno.2026.06.003}
}

RIS

TY  - JOUR
TI  - Atezolizumab in combination with neoadjuvant chemotherapy and interval cytoreductive surgery for patients with newly diagnosed advanced-stage epithelial ovarian cancer: the AdORN study
AU  - Stéphanie Gaillard
AU  - Jack Parker
AU  - Gloria Broadwater
AU  - Linda Duska
AU  - Hope Knochenhauer
AU  - Kari Ring
AU  - Leah McNally
AU  - Paula S. Lee
AU  - Brittany Davidson
AU  - Rebecca Previs
AU  - Haley Moss
AU  - Layne W. Rogers
AU  - Yanwan Dai
AU  - Andrew Berchuck
AU  - Andrew B. Nixon
AU  - John S. Yi
AU  - Michael Bookman
AU  - Kouros Owzar
AU  - Jadee L. Neff
AU  - Jose Conejo-Garcia
AU  - Angeles Alvarez Secord
PY  - 2026
JO  - Gynecologic Oncology
DO  - 10.1016/j.ygyno.2026.06.003
UR  - https://doi.org/10.1016/j.ygyno.2026.06.003
ER  -

APA

Gaillard, S., Parker, J., Broadwater, G., Duska, L., Knochenhauer, H., Ring, K., McNally, L., Lee, P. S., Davidson, B., Previs, R., Moss, H., Rogers, L. W., Dai, Y., Berchuck, A., Nixon, A. B., Yi, J. S., Bookman, M., Owzar, K., Neff, J. L., Conejo-Garcia, J., & Secord, A. A. (2026). Atezolizumab in combination with neoadjuvant chemotherapy and interval cytoreductive surgery for patients with newly diagnosed advanced-stage epithelial ovarian cancer: the AdORN study. Gynecologic Oncology. https://doi.org/10.1016/j.ygyno.2026.06.003

Source records

crossref · retrieved 2026-09-26T09:43:08.039Z